Concord Biotech Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CONCORDBIO.NS | BIOCON.NS | ANTHEM.NS | TITANBIO.BO | 1762.TW | 1777.TWO | |
|---|---|---|---|---|---|---|
| Market cap | 140.75B | 592.87B | 514.81B | 17.07B | 2.36B | 3.44B |
| P/E (TTM) | 50.4 | 121.5 | 84.4 | 50.4 | — | 10.4 |
| Forward P/E | 32.5 | 33.3 | 60.4 | — | 68.2 | — |
| Price/book | 6.9 | 1.7 | 15.7 | 9.4 | 0.7 | 1.3 |
| Dividend yield | 0.58% | 0.15% | 0.23% | 0.12% | — | 5.17% |
| 1-year change | −7.11% | −10.58% | +27.52% | +103.29% | +24.35% | −1.15% |
| Today | +2.62% | +5.10% | +2.84% | +2.40% | −1.44% | −0.26% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All CONCORDBIO.NS news ›Concord Biotech reports 25% revenue growth in Q2 FY27
Concord Biotech announced a robust 25% YoY revenue growth for Q2 FY27, reaching ₹309.1 crore. H1 FY27 revenues also saw a 26% jump to ₹566.6 crore. Growth was broad-based across segments, including oncology. Concord Biotech reports 25%…
Concord Biotech CONCORDBIO Reg 74(5) Certificate Q2 FY27
Kalkine India Concord Biotech (NSE:CONCORDBIO): What Does Its Reg 74(5) Certificate Mean? Source: Krish Capital Pty Ltd Concord Biotech Limited (NSE:CONCORDBIO) submitted a compliance certificate on 07 October 2026 to both NSE and BSE,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- investywise.com1
- kalkine.co.in1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.